Zilico Ltd will present its pioneering cervical cancer diagnostics tool at Medica 2012 – the world’s premier healthcare exhibition.
The British company’s innovative system, which is due to be launched in 2013, offers quicker more accurate detection of cervical dysplasia in real time, removing several weeks of waiting time for diagnosis.
Zilico’s Chief Executive, Mr Sameer Kothari, will present the system at the four-day exhibition, which takes place at the Messe Düsseldorf from 14-17 November. Zilico Ltd will be located at Hall 16 stand G10-3.
ZedScan I, the first application of the device, is positioned within the referral population, will reduce the number of biopsies taken and has the potential to facilitate the wider use of ‘see & treat’ modality.
The system consists of a portable hand-held device, a single-use disposable sleeve and docking station and is safe and painless.
Using electrical impedance spectroscopy technology, it can measure the resistivity of cells and so detect changes as cells progress from normal to precancerous and then to cancerous.
The referral application completed a pivotal European trial of 400 women in 2011 across three hospitals in the UK and Ireland. The company has since been disseminating these results at key scientific meetings across the world, and was recently awarded the ‘Best Scientific Presentation’ at the ASCCP 2012.
As the biggest healthcare exhibition in the world, attracting more than 130,000 visitors over the four days, Mr Kothari is hoping to discuss potential commercial partnerships with sales and marketing companies who are experienced in selling into gynaecology.
Mr Kothari said: “The diagnostic tool, including the recent pivotal trial data, has the potential to make a significant impact on how women are managed within the cervical cancer pathway.
“This makes the Zilico proposition very attractive to those considering potential partnerships and we look forward to meeting interested parties at Medica.”